SOLIGENIX, INC. (Form: 4, Received: 12/21/2012 21:17:32)

Table I - Non-Derivative Securities Acquired, Disposed of, or Beneficially Owned

1.Title of Security
(Instr. 3)

2. Trans. Date

2A. Deemed Execution Date, if any

3. Trans. Code
(Instr. 8)

4. Securities Acquired (A) or Disposed of (D)
(Instr. 3, 4 and 5)

5. Amount of Securities Beneficially Owned Following Reported Transaction(s)
(Instr. 3 and 4)

6. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)

7. Nature of Indirect Beneficial Ownership (Instr. 4)

Code

Amount

(A) or (D)

Price

Common Stock

2,711,392 ⁽¹⁾

I ⁽²⁾

Indirect ⁽²⁾

Common Stock

164,146 ⁽¹⁾

I ⁽³⁾

Indirect ⁽³⁾

Common Stock

59,539 ⁽¹⁾

*Table II - Derivative Securities Beneficially Owned (e.g., puts, calls, warrants, options, convertible securities)*
Common Stock Warrant (warrant to buy)	$5.6 ⁽⁴⁾	12/20/2012	J ⁽⁵⁾		1	9/28/2009	9/27/2014	Common Stock	98,813 ⁽¹⁾	⁽⁵⁾	0	I ⁽²⁾	Indirect ⁽²⁾
Common Stock Warrant (warrant to buy)	$5.6 ⁽⁴⁾	12/20/2012	J ⁽⁵⁾		1	6/18/2010	6/18/2015	Common Stock	258,256 ⁽¹⁾	⁽⁵⁾	0	I ⁽²⁾	Indirect ⁽²⁾
Common Stock Warrant (warrant to buy)	$0.53	12/20/2012	J ⁽⁵⁾	1		6/19/2013	12/19/2017 ⁽⁶⁾	Common Stock	357,069	⁽⁵⁾	1	I ⁽²⁾	Indirect ⁽²⁾
Common Stock Warrant (warrant to buy)	$5.6 ⁽⁴⁾	12/20/2012	J ⁽⁷⁾		1	6/18/2010	6/18/2015	Common Stock	87,804 ⁽¹⁾	⁽⁷⁾	0	I ⁽³⁾	Indirect ⁽³⁾
Common Stock Warrant (warrant to buy)	$0.53	12/20/2012	J ⁽⁷⁾	1		6/19/2013	12/19/2017 ⁽⁶⁾	Common Stock	87,804	⁽⁷⁾	1	I ⁽³⁾	Indirect ⁽³⁾

Table II - Derivative Securities Beneficially Owned (e.g., puts, calls, warrants, options, convertible securities)

1. Title of Derivate Security
(Instr. 3)

2. Conversion or Exercise Price of Derivative Security

3. Trans. Date

3A. Deemed Execution Date, if any

4. Trans. Code
(Instr. 8)

5. Number of Derivative Securities Acquired (A) or Disposed of (D)
(Instr. 3, 4 and 5)

6. Date Exercisable and Expiration Date

7. Title and Amount of Securities Underlying Derivative Security
(Instr. 3 and 4)

8. Price of Derivative Security
(Instr. 5)

9. Number of derivative Securities Beneficially Owned Following Reported Transaction(s) (Instr. 4)

10. Ownership Form of Derivative Security: Direct (D) or Indirect (I) (Instr. 4)

11. Nature of Indirect Beneficial Ownership (Instr. 4)

Code

(A)

(D)

Date Exercisable

Expiration Date

Title

Amount or Number of Shares

Common Stock Warrant (warrant to buy)

$5.6 ⁽⁴⁾

12/20/2012

J ⁽⁵⁾

9/28/2009

9/27/2014

Common Stock

98,813 ⁽¹⁾

⁽⁵⁾

I ⁽²⁾

Indirect ⁽²⁾

Common Stock Warrant (warrant to buy)

$5.6 ⁽⁴⁾

12/20/2012

J ⁽⁵⁾

6/18/2010

6/18/2015

Common Stock

258,256 ⁽¹⁾

⁽⁵⁾

I ⁽²⁾

Indirect ⁽²⁾

Common Stock Warrant (warrant to buy)

$0.53

12/20/2012

J ⁽⁵⁾

6/19/2013

12/19/2017 ⁽⁶⁾

Common Stock

357,069

⁽⁵⁾

I ⁽²⁾

Indirect ⁽²⁾

Common Stock Warrant (warrant to buy)

$5.6 ⁽⁴⁾

12/20/2012

J ⁽⁷⁾

6/18/2010

6/18/2015

Common Stock

87,804 ⁽¹⁾

⁽⁷⁾

I ⁽³⁾

Indirect ⁽³⁾

Common Stock Warrant (warrant to buy)

$0.53

12/20/2012

J ⁽⁷⁾

6/19/2013

12/19/2017 ⁽⁶⁾

Common Stock

87,804

⁽⁷⁾

I ⁽³⁾

Indirect ⁽³⁾

POWER OF ATTORNEY

The undersigned does hereby constitute and appoint each of Fabio Poma and Nicola Wullschleger, with full power of substitution, as the true and lawful attorney-in-fact and agent of the undersigned, and authorizes and designates each of the foregoing attorneys-in-fact to sign on behalf of the undersigned, and to file filings and any amendments thereto, with the Securities and Exchange Commission, made by or on behalf of the undersigned in respect of the beneficial ownership of equity securities of SOLIGENIX, INC. (formerly known as DOR BioPharma, Inc.) held by the undersigned, directly, indirectly or beneficially, pursuant to Sections 13(d), 13(g) and 16 of the Securities Exchange Act of 1934, as amended (the "Exchange Act"), and the rules and regulations thereunder. Each of the undersigned acknowledges that the foregoing attorneys-in-fact, in serving in such capacity at the request of each of the undersigned, are not assuming any of the undersigned's responsibilities to comply with Sections 13(d), 13(g) or 16 of the Exchange Act.

This Power of Attorney shall remain in full force and effect until withdrawn by the undersigned in a signed writing delivered to each of the foregoing attorneys-in-fact.

IN WITNESS WHEREOF, the undersigned has caused this Power of Attorney to be executed as of this 20th day of December 2012.

/s/ Paolo Cavazza

Paolo Cavazza

FORM 4 ☐ Check this box if no longer subject to Section 16. Form 4 or Form 5 obligations may continue. See Instruction 1(b).	UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP OF SECURITIES	OMB APPROVAL OMB Number: 3235-0287 Estimated average burden hours per response... 0.5
	Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934 or Section 30(h) of the Investment Company Act of 1940

1. Name and Address of Reporting Person ^* CAVAZZA PAOLO	2. Issuer Name and Ticker or Trading Symbol SOLIGENIX, INC. [ SNGX ]	5. Relationship of Reporting Person(s) to Issuer (Check all applicable) _____ Director __X__ 10% Owner _____ Officer (give title below) _____ Other (specify below)
(Last) (First) (Middle) VIA TESSERETE, 10	3. Date of Earliest Transaction (MM/DD/YYYY) 12/20/2012
(Street) LUGANO, V8 6900	4. If Amendment, Date Original Filed (MM/DD/YYYY)	6. Individual or Joint/Group Filing (Check Applicable Line) _X _ Form filed by One Reporting Person ___ Form filed by More than One Reporting Person
(City) (State) (Zip)

Explanation of Responses:
(1)	On February 1, 2012, the Issuer completed a reverse stock split of its issued and outstanding shares of common stock at a ratio of 1-for-20, whereby every 20 shares of its common stock was exchanged for one share of its common stock (the "Reverse Stock Split"). These shares were previously reported but the numbers have been changed to reflect the Reverse Stock Split.
(2)	Directly owned by Sigma-Tau Pharmaceuticals, Inc. ("Pharmaceuticals"). Pharmaceuticals is a direct wholly-owned subsidiary of Sigma-Tau America S.A. ("America"). America is a direct wholly-owned subsidiary of Sigma-Tau International S.A. ("International"). International is a direct wholly-owned subsidiary of Sigma-Tau Finanziaria S.p.A. ("Sigma Tau"). Paolo Cavazza directly and indirectly owns 38% of Sigma Tau.
(3)	Directly owned by Sinaf S.A. (formerly Chaumiere Sarl), which is an indirect wholly owned subsidiary of Aptafin S.p.A. ("Aptafin"). Aptafin is owned by Paolo Cavazza and members of his family.
(4)	The exercise prices that were previously reported have been adjusted to reflect the Reverse Stock Split.
(5)	These three reported transactions involved the issuance by the Issuer to Pharmaceuticals of a new warrant in exchange for the surrender by Pharmaceuticals of outstanding warrants.
(6)	The expiration date of the warrant may be accelerated at the Issuer's option if the Issuer's common stock meets certain price thresholds and the common shares underlying the warrant are registered for resale pursuant to an effective registration statement or are freely transferable without volume limitations pursuant to Rule 144 under the Securities Act of 1933, as amended.
(7)	These two reported transactions involved the issuance by the Issuer to Sinaf S.A. of a new warrant in exchange for the surrender by Sinaf of an outstanding warrant.

Reporting Owners
Reporting Owner Name / Address	Relationships
Reporting Owner Name / Address	Director	10% Owner	Officer	Other
CAVAZZA PAOLO VIA TESSERETE, 10 LUGANO, V8 6900		X

Signatures
/s/ Fabio Poma		12/21/2012
^**Signature of Reporting Person		Date

Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.
*	If the form is filed by more than one reporting person, see Instruction 4(b)(v).
**	Intentional misstatements or omissions of facts constitute Federal Criminal Violations. See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).
Note:	File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.
Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB control number.